

Setmelanotide in Pediatric Rare MC4R Pathway Diseases: 12-Month Analysis

Peter Kühnen,¹ Erica L. T. van den Akker,² Ashley H. Shoemaker,³ Uzoma Okorie,⁴ Charles F. Verge,⁵ Ilene Fennoy,⁶ Megan M. Kelsey,⁷ Andrea M. Haqq,⁸ Christian L. Roth,^{9,10} Jill C. Garrison,¹¹ Martin Wabitsch,¹² Sadaf Farooqi,¹³ Jesús Argente^{14,15}

¹Department of Pediatric Endocrinology and Diabetology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ²Division of Pediatric Endocrinology, Department of Pediatrics, Sophia Children's Hospital and Obesity Center CGG, Erasmus University Medical Center, Rotterdam, The Netherlands; ³Ian Burr Division of Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, TN, USA; ⁴Marshfield Clinic Research Institute, Marshfield, WI, USA; ⁵Sydney Children's Hospital Randwick and Paediatrics, University of New South Wales, Sydney, Australia; ⁶Division of Pediatric Endocrinology, Diabetes, and Metabolism, Columbia University Irving Medical Center, New York, NY, USA; ⁷Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA; ⁸Division of Pediatric Endocrinology, University of Alberta, Edmonton, AB, Canada; ⁹Seattle Children's Research Institute, Seattle, WA, USA; ¹⁰Division of Endocrinology, Department of Pediatrics, University of Washington, Seattle, WA, USA; ¹¹Rhythm Pharmaceuticals, Inc., Boston, MA, USA; ¹²Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany; ¹³Wellcome-MRC Institute of Metabolic Science and NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK; ¹⁴Department of Pediatrics and Pediatric Endocrinology, Universidad Autónoma de Madrid, University Hospital Niño Jesús, CIBER "Fisiopatología de la obesidad y nutrición" (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; ¹⁵IMDEA Food Institute, Madrid, Spain

2007868



To download a PDF version of this presentation please scan or visit <https://hcp.rhythmtx.com/publications-presentations/>

Introduction

- Under physiologic conditions, the hypothalamic melanocortin-4 receptor (MC4R) pathway regulates hunger, satiety, energy expenditure, and consequently body weight¹⁻⁴
- Rare variants in MC4R pathway genes may impair MC4R signaling, leading to hyperphagia (an absence of satiety and pathologic, insatiable hunger accompanied by abnormal food-seeking behaviors) and early-onset, severe obesity often beginning in the first years of life⁵⁻⁹
 - This includes patients with proopiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome (BBS)
- Acquired hypothalamic obesity (HO) is an acquired form of obesity characterized by rapid weight gain following insult to the hypothalamus¹⁰⁻¹²
- The MC4R agonist setmelanotide reduced body mass index (BMI) and hunger in clinical trials in pediatric patients aged 2-17 years in these populations and was well tolerated¹³⁻¹⁸
- Because this age range spans different developmental stages, further evaluation of the response to treatment or differences in adverse events (AEs) or events of special interest in refined age groups is important

Objectives

- To report changes in weight-related measures and safety after 12 months of setmelanotide in patients stratified by age groups of 2-5, 6-11, and 12-17 years

Methods

Study design

- Patients aged 2-17 years who enrolled in 5 clinical trials of setmelanotide with
 - POMC deficiency (including variants in *PCSK1*; NCT02896192), LEPR deficiency (NCT03287960), BBS (NCT03746522), rare MC4R pathway diseases (2 to <6 years old; NCT04966741), and acquired HO (NCT04725240) who entered a long-term extension trial (NCT03651765) were included in this analysis
- Changes in BMI Z score (World Health Organization [WHO]) from index trial baseline after 12 months of setmelanotide were assessed
- Safety was evaluated by AE frequency

Previous presentation information: Data in this poster were previously presented at The 62nd Annual ESPE Meeting 2024; November 16-18; Liverpool, UK.

Acknowledgments: This study was sponsored by Rhythm Pharmaceuticals, Inc. Writing and editorial support for this poster were provided under the direction of the authors by MedThink SciCom and funded by Rhythm Pharmaceuticals, Inc.

Disclosures: All authors' institutions received research funding from Rhythm. PK has participated on safety board; AHS, MW, JA, SF, UO have received compensation for advisory board participation, consulting, and/or lectures; AMH and JA are BBS advisory board members; and JCG is an employee and receives stock options from Rhythm Pharmaceuticals, Inc.

References: 1. da Fonseca et al. *J Diabetes Complications*. 2017;31:1549-1561. 2. Yazdi et al. *PeerJ*. 2015;3:e856. 3. Farooqi, O'Rahilly. *Nat Clin Pract Endocrinol Metab*. 2008;4:569-577. 4. Vaisse et al. *Cold Spring Harb Perspect Biol*. 2017;9:a028217. 5. Forsythe et al. *Orphanet J Rare Dis*. 2023;18:182. 6. Wabitsch et al. *J Endocr Soc*. 2022;6:bvac057. 7. Wabitsch et al. *Adv Ther*. 2022;39:1772-1783. 8. Pomeroy et al. *Pediatr Obes*. 2021;16:e12703. 9. Kohlsdorf et al. *Int J Obes (Lond)*. 2018;42:1602-1609. 10. Kim, Choi. *Ann Pediatr Endocrinol Metab*. 2013;18:161-167. 11. Rose et al. *Obesity (Silver Spring)*. 2018;26:1727-1732. 12. Dimitri. *Front Endocrinol (Lausanne)*. 2022;13:846880. 13. Huvenne et al. *Obes Facts*. 2016;9:158-173. 14. Clément et al. *Lancet Diabetes Endocrinol*. 2020;8:960-970. 15. Kühnen et al. *N Engl J Med*. 2016;375:240-246. 16. Haqq et al. *Lancet Diabetes Endocrinol*. 2022;10:859-868. 17. Roth et al. *Lancet Diabetes Endocrinol*. 2024;12:380-389. 18. Argente et al. *Lancet Diabetes Endocrinol*. Forthcoming 2024. 19. WHO Child Growth Standards. <https://www.who.int/publications/i/item/924154693X>. Accessed April 10, 2025.

Results

Patient disposition and baseline characteristics


- A total of 50 pediatric patients were included in the analysis at baseline including those with POMC (n=9) or LEPR (n=7) deficiencies, BBS (n=21), and acquired HO (n=13; Table 1)

Table 1. Patient Baseline Characteristics

	POMC, age range, y			LEPR, age range, y			BBS, age range, y			Acquired HO, age range, y		
	2-5	6-11	12-17	2-5	6-11	12-17	2-5	6-11	12-17	2-5	6-11	12-17
n	3	2	4	4	0	3	5	3	13	0	5	8
Sex, n												
Female	-	1	2	2	-	2	3	2	6	-	2	2
Male	3	1	2	2	-	1	2	1	7	-	3	6
Race, n												
White	-	1	3	3	-	3	4	3	11	-	4	8
Black	-	-	-	-	-	-	-	-	1	-	1	-
Other*	3	1	1	1	-	-	1	-	1	-	-	1
Hispanic or Latinx, n												
Yes	-	1	-	1	-	-	-	-	-	-	2	1
No	3	1	4	3	-	3	5	3	13	-	3	7
Weight, mean (SD), kg	36.8 (5.3)	63.9 (8.0)	122.7 (12.9)	51.0 (12.4)	-	108.5 (13.6)	28.3 (13.0)	83.3 (24.5)	101.4 (27.7)	-	70.6 (22.1)	111.9 (21.7)
BMI Z score (WHO), mean (SD)	7.52 (0.63)	2.65 (0.01)	3.70 (0.30)	13.17 (2.85)	-	3.47 (0.31)	4.23 (0.96)	4.59 (1.05)	3.58 (1.32)	-	4.65 (0.84)	3.49 (0.52)

*Other includes Arabic, Moroccan, Middle Eastern, native Hawaiian/Pacific islander, Asian, or not reported. BBS, Bardet-Biedl syndrome; BMI, body mass index; HO, hypothalamic obesity; LEPR, leptin receptor deficiency; POMC, proopiomelanocortin deficiency; SD, standard deviation; WHO, World Health Organization. BMI Z scores were calculated using WHO Child Growth Standards.¹⁹

Figure. Mean BMI Z Score (WHO) Reduction at 52 Weeks



BMI Z scores were calculated using WHO Child Growth Standards.¹⁹ Given the small sample size, statistical comparisons were not performed between age subgroups. BBS, Bardet-Biedl syndrome; BMI, body mass index; HO, hypothalamic obesity; LEPR, leptin receptor deficiency; NR, not reported; POMC, proopiomelanocortin deficiency; WHO, World Health Organization.

Efficacy outcomes

- There were 5 patients who discontinued treatment before Week 52 (1 patient with LEPR deficiency was lost to follow-up, 2 patients with BBS and 2 patients with acquired HO discontinued because of AEs); the measurements of these patients are not included in Week-52 efficacy calculations
- The mean BMI Z score (WHO) was reduced from baseline in all groups, with greater reductions generally observed in younger age groups (Figure)

Safety outcomes

- Of the 50 patients, all had AEs of any causality during the 52-week period (Table 2)
- The most frequent AEs ($\geq 40\%$) were skin hyperpigmentation (36/50; 72%), injection site erythema (22/50; 44%), vomiting (22/50; 44%), nausea (20/50; 40%), and injection site pruritus (20/50; 40%)
- AE frequency and severity did not differ substantially by age group, and there were no serious treatment-related AEs

Table 2. Adverse Events

	All, age range, y	POMC, age range, y			LEPR, age range, y			BBS, age range, y			Acquired HO, age range, y		
	2-17	2-5	6-11	12-17	2-5	6-11	12-17	2-5	6-11	12-17	2-5	6-11	12-17
No. of patients	50	3	2	4	4	-	3	5	3	13	-	5	8
Any AE	50 (100)	3	2	4	4	-	3	5	3	13	-	5	8
AE related to study drug	50 (100)	3	2	4	4	-	3	5	3	13	-	5	8
AE leading to dose interruption or decrease	17 (34)	2	2	1	1	-	0	1	1	3	-	2	4
AE leading to discontinuation	4 (8)	0	1	0	0	-	0	0	0	2	-	0	1
Serious treatment-related AE	0 (0)	0	0	0	0	-	0	0	0	0	-	0	0
AE resulting in death	0 (0)	0	0	0	0	-	0	0	0	0	-	0	0
AEs $\geq 25\%$, any causality													
Skin hyperpigmentation	36 (72)	3	2	4	2	-	3	4	2	10	-	1	5
Vomiting	22 (44)	2	0	4	2	-	0	3	2	5	-	1	3
Injection site erythema	22 (44)	0	2	4	0	-	3	2	2	8	-	0	1
Nausea	20 (40)	0	1	4	1	-	3	0	1	3	-	2	5
Injection site pruritus	20 (40)	0	2	2	1	-	2	3	2	6	-	0	2
Headache	16 (32)	0	1	2	0	-	2	1	1	6	-	1	2
COVID-19	15 (30)	0	0	1	2	-	3	0	0	5	-	1	3
Upper respiratory infection	15 (30)	3	1	4	1	-	1	0	0	1	-	2	2
Spontaneous erections	8 (29)*	1	0	0	0	-	0	0	1	1	-	0	5
Injection site induration	14 (28)	0	0	0	1	-	3	0	2	4	-	2	2
Injection site pain	13 (26)	0	0	1	0	-	1	1	2	5	-	1	2
Injection site bruising	13 (26)	1	2	0	0	-	2	3	2	3	-	0	0
AEs of special interest <25%													
Depression	5 (10)	0	1	0	0	-	2	0	0	2	-	0	0
Suicidal ideation	3 (6)	0	1	0	0	-	0	0	0	1	-	0	1
Melanocytic nevus	9 (18)	2	1	1	1	-	0	1	0	3	-	0	0

Values are the n or n (%). *Male patients only (n=28). AE, adverse event; BBS, Bardet-Biedl syndrome; HO, hypothalamic obesity; LEPR, leptin receptor deficiency; POMC, proopiomelanocortin deficiency.

- Serious AEs and AEs leading to study discontinuation or dose reduction during the 52 weeks occurred in 4 patients (2 BBS; 2 acquired HO)
 - A 12-year-old patient with BBS withdrew from the study at day 167 because of recurrence of AEs unrelated to the study drug (headaches, leg pain, and belligerent behavior)
 - Another 12-year-old patient with BBS experienced treatment-related AEs of nausea and vomiting that were moderate in intensity but led to treatment discontinuation on day 21
 - A 13-year-old patient with acquired HO experienced a treatment-related AE of vomiting, which was mild in intensity but resulted in a temporary dose reduction of study medication
 - A 17-year-old patient with acquired HO experienced a serious AE (*Clostridium difficile*) considered not related to setmelanotide, for which she was hospitalized; this caused disruption of the per-protocol dose escalation (Weeks 2 to 4), and the patient had nausea and vomiting throughout the study, completing the Week-16 visit on Day 113

Conclusions

- In this cross-sectional analysis, regardless of age, pediatric patients with obesity related to POMC or LEPR deficiencies, BBS, and acquired HO achieved clinically meaningful improvements in weight-related measures with no new safety signals
- The greater absolute reduction in BMI Z score among those ages 2-5 years across obesity causes may reflect overall higher baseline scores and highlights the importance of early intervention
 - Conversely, development-related body composition changes may affect BMI measurement across age subgroups
- The safety profile of setmelanotide was consistent across age groups and obesity cause
- More work is needed to understand the variation in response across obesity cause and analyze the impact beyond changes in weight-related measures alone (eg, body composition, hyperphagia, and quality of life)